9-(2'-C-methyl-β-D-ribofuranosyl)-6-(hydroxylamino)purine | 565435-18-9

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 9-(2'-C-methyl-β-D-ribofuranosyl)-6-(hydroxylamino)purine
• 英文别名: 2-(6-Hydroxyamino-purin-9-yl)-5-hydroxymethyl-3-methyl-tetrahydro-furan-3,4-diol；(2R,3R,4R,5R)-2-[6-(hydroxyamino)purin-9-yl]-5-(hydroxymethyl)-3-methyloxolane-3,4-diol
• CAS: 565435-18-9
• 化学式: C₁₁H₁₅N₅O₅
• 分子量: 297.271
• InChiKey: LKTOBEVKANRCGI-YRKGHMEHSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.5
• 重原子数：
  21
• 可旋转键数：
  3
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.55
• 拓扑面积：
  146
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  9-(2'-C-methyl-β-D-ribofuranosyl)-6-(hydroxylamino)purine 在 吡啶 、 1H-1,2,4-三唑 作用下， 反应 14.0h， 生成 N-[9-((2R,3R,4R,5R)-3,4-Dihydroxy-5-hydroxymethyl-3-methyl-tetrahydro-furan-2-yl)-9H-purin-6-yl]-N-hydroxy-propionamide
  参考文献：
  名称：

  Synthesis of 9-(2-β-C-methyl-β-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication

  摘要：

  A series of 9-(2'-beta-C-methyl-p-D-ribofuranosyl)-6-substituted purine derivatives were synthesized as potential inhibitors of HCV RNA replication. Their inhibitory activities in a cell based HCV replicon assay were reported. A prodrug approach was used to further improve the potency of these compounds by increasing the intracellular levels of 5'-monophosphate metabolites. These nucleotide prodrugs showed much improved inhibitory activities of HCV RNA replication. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.020
• 作为产物：
  描述：

  6-氯-9-(2,3,5-三苯甲酰氧基-2-C-甲基-beta-D-呋喃核糖基)-9H-嘌呤 在 氰化钠 、 羟胺 作用下， 以 甲醇 为溶剂， 反应 22.0h， 生成 9-(2'-C-methyl-β-D-ribofuranosyl)-6-(hydroxylamino)purine
  参考文献：
  名称：

  Synthesis of 9-(2-β-C-methyl-β-d-ribofuranosyl)-6-substituted purine derivatives as inhibitors of HCV RNA replication

  摘要：

  A series of 9-(2'-beta-C-methyl-p-D-ribofuranosyl)-6-substituted purine derivatives were synthesized as potential inhibitors of HCV RNA replication. Their inhibitory activities in a cell based HCV replicon assay were reported. A prodrug approach was used to further improve the potency of these compounds by increasing the intracellular levels of 5'-monophosphate metabolites. These nucleotide prodrugs showed much improved inhibitory activities of HCV RNA replication. (C) 2004 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2004.11.020

文献信息

• Nucleoside derivatives for treating hepatitis C virus infection
  申请人：Genelabs Technologies, Inc.

  公开号：US20040147464A1

  公开（公告）日：2004-07-29

  Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.

  本文揭示了用于治疗丙型肝炎病毒感染的化合物、组合物和方法。
• NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION
  申请人：Roberts Christopher Don

  公开号：US20080249060A1

  公开（公告）日：2008-10-09

  Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.

  本发明涉及用于治疗丙型肝炎病毒感染的化合物、组合物和方法。
• US7425547B2
  申请人：——

  公开号：US7425547B2

  公开（公告）日：2008-09-16
• US7629320B2
  申请人：——

  公开号：US7629320B2

  公开（公告）日：2009-12-08
• [EN] NUCLEOSIDE DERIVATIVES FOR TREATING HEPATITIS C VIRUS INFECTION<br/>[FR] DERIVES NUCLEOSIDIQUES DESTINES AU TRAITEMENT DE L'INFECTION PAR LE VIRUS DE L'HEPATITE C
  申请人：GENELABS TECH INC

  公开号：WO2003093290A2

  公开（公告）日：2003-11-13

  Disclosed are compounds, compositions and methods for treating hepatitis C virus infections.